Hepatitis C Virus

Duke, Johns Hopkins to lead first comparative trial of therapies

Published in Medical Letter on the CDC and FDA, October 19th, 2003

Researchers from Duke University Medical Center and the Johns Hopkins University School of Medicine will lead the first ever direct comparison of the two leading treatments for hepatitis C infection, a study they hope will help refine treatment practices to maximize benefit for patients.

Approximately 3.9 million Americans are infected with the hepatitis C virus, according to the U.S. Centers for Disease Control and Prevention. The virus, which affects the liver, is spread through contact with human blood. Approximately 70% of infected patients suffer from chronic hepatitis C infection, which can cause cirrhosis and liver cancer. Hepatitis C is the leading indication...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-10-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry